Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTW0CMT)

• DTT Name: Voltage-gated potassium channel Kv1.5 (KCNA5) DTT Info
• Gene Name: KCNA5

Molecule-Related Drug & Molecule List

1 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dronedarone	DMA8FS5	Angina pectoris	BA40	Approved	[1]

5 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BMS-919373	DMN28WK	Atrial fibrillation	BC81.3	Phase 2	[2]
BMS-394136	DMGDJQR	Arrhythmia	BC9Z	Phase 1	[3]
IQB-9302	DMET0H4	Pain	MG30-MG3Z	Phase 1	[4]
XEN-D0101	DMU0V45	Atrial fibrillation	BC81.3	Phase 1	[5]
XEN-D0103	DMR0U4V	Atrial fibrillation	BC81.3	Phase 1	[6]

1 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
T-226296	DMJ6P9U	Obesity	5B81	Preclinical	[1]

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zatebradine	DMNYKOT	Angina pectoris	BA40	Terminated	[7]

20 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
2-amino-2-phenyl-1,1-di(pyridin-3-yl)ethanol	DM14HCY	Discovery agent	N.A.	Investigative	[8]
2-morpholino-1,1,2-triphenylethanol	DMFHTEG	Discovery agent	N.A.	Investigative	[8]
2-morpholino-1,1-di(pyridin-3-yl)hexan-1-ol	DMH89O5	Discovery agent	N.A.	Investigative	[8]
2-morpholino-1,1-di(pyridin-3-yl)octan-1-ol	DMDMVA1	Discovery agent	N.A.	Investigative	[8]
2-morpholino-2-phenyl-1,1-di(pyridin-3-yl)ethanol	DM3V5AB	Discovery agent	N.A.	Investigative	[8]
2-phenoxy-1-(2-p-tolylthiazolidin-3-yl)ethanone	DMQX7FW	Discovery agent	N.A.	Investigative	[9]
2-phenyl-1,1-di(pyridin-3-yl)ethanol	DMERNSK	Discovery agent	N.A.	Investigative	[8]
3-(4-methoxybenzyloxy)-2-phenylthiazolidin-4-one	DMFRZGS	Discovery agent	N.A.	Investigative	[9]
3-(benzyloxy)-2-(4-chlorophenyl)thiazolidin-4-one	DMD4WHN	Discovery agent	N.A.	Investigative	[9]
3-methyl-2-morpholino-1,1-diphenylbutan-1-ol	DMKWAV6	Discovery agent	N.A.	Investigative	[8]
4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one	DMKMH5L	Discovery agent	N.A.	Investigative	[10]
clofilium	DMQ37OP	Discovery agent	N.A.	Investigative	[11]
DPO-1	DMHCZP0	Atrial fibrillation	BC81.3	Investigative	[6]
N-Benzyl-2-(toluene-4-sulfonylamino)-benzamide	DM3C0P2	Discovery agent	N.A.	Investigative	[12]
N-Phenethyl-2-(toluene-4-sulfonylamino)-benzamide	DM1BU5P	Discovery agent	N.A.	Investigative	[12]
NIP-142	DMV53PH	Atrial fibrillation	BC81.3	Investigative	[1]
RS-100302	DM63NGW	Atrial fibrillation	BC81.3	Investigative	[1]
S-9947	DMHB6UY	Atrial fibrillation	BC81.3	Investigative	[1]
XEN-D0104	DM1EHG5	Atrial fibrillation	BC81.3	Investigative	[6]
[14C]TEA	DM6SFYH	Discovery agent	N.A.	Investigative	[13]

References

• [1] New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
• [2] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035504)
• [3] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [4] Stereoselective effects of the enantiomers of a new local anaesthetic, IQB-9302, on a human cardiac potassium channel (Kv1.5). Br J Pharmacol. 2001 Jan;132(2):385-92.
• [5] Human electrophysiological and pharmacological properties of XEN-D0101: a novel atrial-selective Kv1.5/IKur inhibitor. J Cardiovasc Pharmacol. 2013 May;61(5):408-15.
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 542).
• [7] DOI: 10.1161/01.CIR.94.3.562
• [8] Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2493-6.
• [9] Evolution of thiazolidine-based blockers of human Kv1.5 for the treatment of atrial arrhythmias. Bioorg Med Chem Lett. 2007 Jan 1;17(1):282-4.
• [10] Substituted N-{3-[(1,1-dioxido-1,2-benzothiazol-3-yl)(phenyl)amino]propyl}benzamide analogs as potent Kv1.3 ion channel blockers. Part 2. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6989-92.
• [11] Mechanism of clofilium block of the human Kv1.5 delayed rectifier potassium channel. Mol Pharmacol. 1995 Jan;47(1):198-205.
• [12] Pharmacophore-based search, synthesis, and biological evaluation of anthranilic amides as novel blockers of the Kv1.5 channel. Bioorg Med Chem Lett. 2004 Jun 7;14(11):2823-7.
• [13] Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol. 1994 Jun;45(6):1227-34.